Lobar Yttrium-90 Radioembolization with BSA-Based Dosimetry for Unresectable Hepatocellular Carcinoma: Baseline Vascularity Predicts Responders to the Combination with Targeted Therapy or Immune Checkpoint Inhibition.

Lüdemann WM, Kahn J, Herzler P, Collettini F, Savic LJ, Mohr R, Fehrenbach U, Auer TA, Gebauer B, Amthauer H, Wieners G

Open source

DOI
10.2147/jhc.s553808
Published
2025
Container
Journal of hepatocellular carcinoma
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.2147/jhc.s553808,
  title = {Lobar Yttrium-90 Radioembolization with BSA-Based Dosimetry for Unresectable Hepatocellular Carcinoma: Baseline Vascularity Predicts Responders to the Combination with Targeted Therapy or Immune Checkpoint Inhibition.},
  author = {Lüdemann WM and Kahn J and Herzler P and Collettini F and Savic LJ and Mohr R and Fehrenbach U and Auer TA and Gebauer B and Amthauer H and Wieners G},
  year = {2025},
  journal = {Journal of hepatocellular carcinoma},
  doi = {10.2147/jhc.s553808},
  url = {https://doi.org/10.2147/jhc.s553808}
}

RIS

TY  - JOUR
TI  - Lobar Yttrium-90 Radioembolization with BSA-Based Dosimetry for Unresectable Hepatocellular Carcinoma: Baseline Vascularity Predicts Responders to the Combination with Targeted Therapy or Immune Checkpoint Inhibition.
AU  - Lüdemann WM
AU  - Kahn J
AU  - Herzler P
AU  - Collettini F
AU  - Savic LJ
AU  - Mohr R
AU  - Fehrenbach U
AU  - Auer TA
AU  - Gebauer B
AU  - Amthauer H
AU  - Wieners G
PY  - 2025
JO  - Journal of hepatocellular carcinoma
DO  - 10.2147/jhc.s553808
UR  - https://doi.org/10.2147/jhc.s553808
ER  - 

APA

WM, L., J, K., P, H., F, C., LJ, S., R, M., U, F., TA, A., B, G., H, A., & G, W. (2025). Lobar Yttrium-90 Radioembolization with BSA-Based Dosimetry for Unresectable Hepatocellular Carcinoma: Baseline Vascularity Predicts Responders to the Combination with Targeted Therapy or Immune Checkpoint Inhibition.. Journal of hepatocellular carcinoma. https://doi.org/10.2147/jhc.s553808

Source records